semaglutide glp 1 receptor agonist vs. Tirzepatide: Which GLP-1 Wins? PDB-101: Diabetes Mellitus: Diabetes Mellitus:
Description
It is crucial to note that in most CVOTs the primary endpoint was a composite endpoint of major adverse cardiovascular events (MACE), with HF hospitalisation typically a prespecified secondary or exploratory outcome
2023 Sep 7;389(10):877-888
Alternative Weight-Loss Solutions: The efficacy and popularity of GLP-1RA drugs for weight loss are placing pressure on and could replace alternative weight-loss solutions, such as bariatric surgery or lifestyle-focused weight-loss programs
[DOI] [PubMed] [Google Scholar] 486.Zhao A.Z., Zhao H., Teague J., Fujimoto W., Beavo J.A
American Journal of Physiology
